CR8929A - Polimorfo ii de rapamicina y usos del mismo - Google Patents

Polimorfo ii de rapamicina y usos del mismo

Info

Publication number
CR8929A
CR8929A CR8929A CR8929A CR8929A CR 8929 A CR8929 A CR 8929A CR 8929 A CR8929 A CR 8929A CR 8929 A CR8929 A CR 8929A CR 8929 A CR8929 A CR 8929A
Authority
CR
Costa Rica
Prior art keywords
same
rapamycin
polymorph
rapamycin polymorph
provides
Prior art date
Application number
CR8929A
Other languages
English (en)
Inventor
Tianmin Zhu
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8929(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8929A publication Critical patent/CR8929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion provee polimorfo forma II de rapamicina; esta invencion provee procedimientos para preparar polimorfomo forma II de rapamicina y composiciones farmaceuticas que incluyen polimorfo forma II de rapamicina.
CR8929A 2004-08-20 2007-02-15 Polimorfo ii de rapamicina y usos del mismo CR8929A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60309604P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
CR8929A true CR8929A (es) 2007-08-28

Family

ID=35431373

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8929A CR8929A (es) 2004-08-20 2007-02-15 Polimorfo ii de rapamicina y usos del mismo

Country Status (22)

Country Link
US (1) US7282505B2 (es)
EP (1) EP1781671A1 (es)
JP (1) JP2008510710A (es)
KR (1) KR20070051863A (es)
CN (1) CN101039948A (es)
AR (1) AR050374A1 (es)
AU (1) AU2005277407A1 (es)
BR (1) BRPI0514407A (es)
CA (1) CA2575887A1 (es)
CR (1) CR8929A (es)
EC (1) ECSP077268A (es)
GT (1) GT200500223A (es)
IL (1) IL181170A0 (es)
MX (1) MX2007002044A (es)
NO (1) NO20071050L (es)
PA (1) PA8642501A1 (es)
PE (1) PE20060649A1 (es)
RU (1) RU2007104518A (es)
SV (1) SV2006002201A (es)
TW (1) TW200608973A (es)
WO (1) WO2006023627A1 (es)
ZA (1) ZA200701453B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1553940T3 (da) 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
MX2009001067A (es) * 2006-07-25 2009-06-17 Abbott Lab Formas cristalinas de analogos de rapamicina.
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US20110275798A1 (en) * 2009-01-21 2011-11-10 Rakesh Bhaiyyaram Mendhe Method for Determination of Sirolimus Stability and Process for Preparing Its Stable Form
US20120231037A1 (en) 2009-02-02 2012-09-13 Yissum Research Development Companyof the Hebrew U Crystalline drug-containing coatings
WO2011049659A2 (en) * 2009-08-05 2011-04-28 The Government Of United States, As Represented By The Secretary Of The Army Novel use and method of rapamycin to treat toxic shock
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2855619A1 (en) 2011-11-15 2013-05-23 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2 - signal transducer and activator of transcription 5 pathway
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
KR20160120739A (ko) * 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
RU2718583C2 (ru) 2014-04-04 2020-04-08 ЭйАй ТЕРАПЬЮТИКС, ИНК. Рапамицин-содержащая композиция, вводимая путем ингаляции для лечения возрастных заболеваний
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN106478663A (zh) * 2015-08-26 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种依维莫司的干燥方法
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN113939324A (zh) 2019-04-08 2022-01-14 巴德外周血管股份有限公司 在经改性装置表面上具有药物洗脱涂层的医疗装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
UA41884C2 (uk) 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів

Also Published As

Publication number Publication date
CA2575887A1 (en) 2006-03-02
ZA200701453B (en) 2010-08-25
IL181170A0 (en) 2007-07-04
TW200608973A (en) 2006-03-16
ECSP077268A (es) 2007-03-29
EP1781671A1 (en) 2007-05-09
CN101039948A (zh) 2007-09-19
SV2006002201A (es) 2006-05-09
AU2005277407A1 (en) 2006-03-02
BRPI0514407A (pt) 2008-06-10
US7282505B2 (en) 2007-10-16
MX2007002044A (es) 2007-03-29
KR20070051863A (ko) 2007-05-18
PE20060649A1 (es) 2006-08-10
US20060040971A1 (en) 2006-02-23
WO2006023627A8 (en) 2006-11-30
AR050374A1 (es) 2006-10-18
PA8642501A1 (es) 2006-05-16
NO20071050L (no) 2007-05-15
RU2007104518A (ru) 2008-09-27
GT200500223A (es) 2006-03-09
WO2006023627A1 (en) 2006-03-02
JP2008510710A (ja) 2008-04-10

Similar Documents

Publication Publication Date Title
CR8929A (es) Polimorfo ii de rapamicina y usos del mismo
PA8667201A1 (es) Nuevos compuestos farmaceuticos
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
ATE528989T1 (de) Kristalline feste rasagilin-base
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
MY154898A (en) P70 s6 kinase inhibitors
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CR10444A (es) Anticuerpo humanizado de c-kit
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
AR052447A1 (es) Etansulfonato de 1-(2-metipropil)-1h-imidazo[4,5-c] [1,5] naftiridin-4- amina y metansulfonato de 1-(2- metipropil)-1h-imidazo[4,5 -c] [1,5] naftiridin-4-amina
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CR9257A (es) Polimorfo cci-779 y uso del mismo
CR9786A (es) Compuestos de bencimidazol-tiofeno
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
HN2006029142A (es) Proceso
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
ECSP088691A (es) Procesos para la síntesis convergente de los derivados de caliqueamicina
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)